Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- IMVT
- Price
- 26.18
- Stock movement up
- +0.16 (0.61%)
- Company name
- Immunovant Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 5.27B
- Ent value
- 4.82B
- Price/Sales
- 32966.60
- Price/Book
- 10.15
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 12.18%
- 1 year return (CAGR)
- 10.98%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
IMVT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 32966.60 |
| Price to Book | 10.15 |
| EV to Sales | 30100.25 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 201.48M |
| EPS (TTM) | -2.68 |
| FCF per share (TTM) | -2.48 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 160.00K |
| Gross profit (TTM) | -126.00K |
| Operating income (TTM) | -487.11M |
| Net income (TTM) | -464.69M |
| EPS (TTM) | -2.68 |
| EPS (1y forward) | -3.00 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -78.75% |
| Operating margin (TTM) | -214748.36% |
| Profit margin (TTM) | -214748.36% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 521.87M |
| Net receivables | 1.97M |
| Total current assets | 573.55M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 582.96M |
| Accounts payable | 6.92M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 63.25M |
| Total liabilities | 63.25M |
| Shareholder's equity | 519.71M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -430.95M |
| Capital expenditures (TTM) | 381.00K |
| Free cash flow (TTM) | -431.33M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -89.41% |
| Return on Assets | -79.71% |
| Return on Invested Capital | -89.41% |
| Cash Return on Invested Capital | -83.00% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 25.99 |
| Daily high | 26.55 |
| Daily low | 25.85 |
| Daily Volume | 1.65M |
| All-time high | 52.71 |
| 1y analyst estimate | 39.27 |
| Beta | 0.56 |
| EPS (TTM) | -2.68 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 18 Feb 2026 |
Downside potential
Loading...
Downside potential data
| IMVT | S&P500 | |
| Current price drop from All-time high | -50.33% | -0.89% |
| Highest price drop | -74.75% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -60.76% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
5.27B
Marketcap category
Mid-cap
Description
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Employees
362
Website
Investor relations
-
SEC filings
CEO
Peter Salzmann
Country
USA
City
New York
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page